The 4th Spanish Breast Congress, in Madrid

The 4th Spanish Breast Congress, in Madrid

This congress will take place in IFEMA, during the next 17 to 19 October.

More than 1,200 specialists in breast pathologies will debate together  about the main developments, treatments, prevention and diagnosis.




Once again, the hosting city for the 4CEMA, the Spanish Breast Congress, is Madrid. A perfect location to hold this meeting, which will bring more than 1200 specialists together. The 4CEMA is, undoubtedly, the benchmark Spanish congress for all professionals dedicated to breast pathology from a multidisciplinary point of view.

4CEMA will take place from October 17th to 19th at the IFEMA North Convention Center, a working environment that allows interpersonal relationship. The most important developments and key highlights on breast pathology and, specially, breast cancer will be discussed here.

Scientist programme

Its attractive programme will be developed by national and international experts, specialized on breast cancer prevention, diagnosis and treatment. Some of the most interesting lectures deal with personalization of the radiological screening, avoidance of treatments with no therapeutic value, importance social media for breast units, artificial intelligence, neoadjuvant approach or recurrence rates, as the highest expression of multidisciplinarity.

About the organizers

Promoted by SESPM (the Spanish Society on Senologic and Breast Pathology), SEDIM (the Spanish Society on Breast Imaging) and SETS (the Nursery and Senologic Technicians Section), it also counts with the participation of the most important Spanish investigation groups, GEICAM and SOLTI, and other societies dedicated to this pathology: AECIMA, AEC, AETR, SEOQ, SEOR, SEGO and SEAP.

As special guests, we count on Prof. Armando Giuliano among others. This breast surgeon changed the armpit surgical approach in a way that avoids lymphadenectomy, and hence its implications in most women (even with a committed armpit), without compromising its prognosis.

Further info, by clicking here.